Research programme: costimulatory trispecific T cell engagers therapeutics - Zymeworks
Latest Information Update: 05 May 2023
At a glance
- Originator Zymeworks
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 18 Apr 2023 Research programme: costimulatory trispecific T cell engagers therapeutics - Zymeworks is available for licensing as of 18 Apr 2023. https://www.zymeworks.com/partners/ (Zymeworks pipeline, April 2023)
- 18 Apr 2023 Early research in Solid tumours in Canada (Parenteral) before April 2023
- 14 Apr 2023 Preclinical trials in Solid tumours in Canada (Parenteral) (before April 2023)